Dr Paul Joyce is Head of the Translational Nanomedicine & Biotherapeutics Group at the University of South Australia where his research focuses on harnessing drug delivery approaches for transforming therapeutic outcomes across a wide range of diseases, including cancer, mental health, and antimicrobial resistance. Working at the interface of materials science and drug development, Dr Joyce engages closely with key stakeholders who enable clinical and commercial translation of his research, including the pharmaceutical industry, clinicians, and health consumers. Dr Joyce’s leadership within this field is evidenced through his publication of over 70 peer reviewed papers in leading international journals, 3 book chapters, and 3... Read more
About me
Dr Paul Joyce is Head of the Translational Nanomedicine & Biotherapeutics Group at the University of South Australia where his research focuses on harnessing drug delivery approaches for transforming therapeutic outcomes across a wide range of diseases, including cancer, mental health, and antimicrobial resistance. Working at the interface of materials science and drug development, Dr Joyce engages closely with key stakeholders who enable clinical and commercial translation of his research, including the pharmaceutical industry, clinicians, and health consumers. Dr Joyce’s leadership within this field is evidenced through his publication of over 70 peer reviewed papers in leading international journals, 3 book chapters, and 3 granted international patents for novel nanomedicine inventions. Further, Dr Joyce is a Director of the Australian Controlled Release Society, the leading society for delivery science, and has been awarded over $9M in funding to support his research activities, including serving as a current Hospital Research Foundation Fellow and Cancer Council SA Fellow.
About me
About me
Date | Title |
---|---|
14/12/2018 |
Could eating DIRT be the cure for obesity?, https://www.dailymail.co.uk/health/article-6493241/How-pill-mud-cure-obesity-soaking-fat-stop-body-absorbing-it.html |
About me
Doctor of Philosophy University of South Australia
Postdoctoral Research Fellow - Chalmers University of Technology, 2017 - 2019
Doctor of Philosophy (Pharmacy) - University of South Australia, 2012 - 2016
Bachelor of Engineering (Honours) (Pharmaceutical and Chemical) - University of Adelaide, 2007 - 2011
Designing, engineering and applying innovative drug delivery solutions that overcome key biopharmaceutical challenges for the benefit of the wider community. Cutting edge biophysical and synthesis techniques are employed to develop novel strategies and technologies that are well-positioned for rapid clinical translation.
Research
Excludes commercial-in-confidence projects.
Omega-3 Fatty Acid Quantification in Patient Plasma Samples, Pharmako Biotechnologies Pty Ltd, 15/10/2024 - 31/01/2025
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2019 |
17
16
120
|
2019 |
Open access
82
75
4
|
2017 |
21
19
5
|
2016 |
34
33
|
2015 |
30
28
4
|
Year | Output |
---|---|
2024 |
Open access
4
|
2024 |
Open access
71
|
2024 |
Open access
2
|
2024 |
Open access
|
2024 |
Open access
2
3
|
2024 |
Open access
|
2024 |
Open access
5
44
|
2024 |
Open access
6
|
2024 |
|
2024 |
Open access
1
|
2024 |
Open access
1
|
2024 |
Open access
|
2024 |
Open access
4
84
|
2024 |
Open access
|
2024 |
Open access
2
|
2024 |
Open access
1
|
2024 |
Open access
3
|
2024 |
Open access
|
2024 |
1
1
|
2024 |
2
4
|
2023 |
Open access
3
3
64
|
2023 |
Open access
4
|
2023 |
Open access
10
11
|
2023 |
Open access
9
8
|
2023 |
Open access
41
|
2023 |
5
|
2023 |
Open access
11
5
|
2023 |
Open access
7
7
21
|
2023 |
Open access
18
18
4
|
2023 |
Open access
14
8
|
2023 |
Open access
6
4
|
2023 |
11
12
|
2023 |
4
4
6
|
2022 |
3
3
3
|
2022 |
8
8
66
|
2022 |
Open access
9
9
121
|
2022 |
Open access
262
|
2022 |
Open access
5
6
3
|
2022 |
Open access
8
5
333
|
2022 |
Open access
5
3
1
|
2021 |
Open access
8
8
|
2021 |
Open access
23
23
4
|
2021 |
Open access
8
8
4
|
2021 |
5
5
1
|
2021 |
58
56
11
|
2021 |
Open access
9
9
10
|
2020 |
Open access
8
8
2
|
2020 |
10
9
3
|
2020 |
20
17
4
|
2020 |
7
6
1
|
2020 |
16
13
|
2020 |
40
38
2
|
2020 |
Open access
7
7
|
2020 |
Open access
13
13
13
|
2019 |
Open access
17
17
|
2019 |
17
16
120
|
2019 |
12
11
2
|
2019 |
Open access
82
75
4
|
2019 |
39
34
|
2018 |
17
14
5
|
2018 |
20
18
7
|
2018 |
22
21
|
2018 |
26
24
2
|
2017 |
Open access
10
9
|
2017 |
21
19
5
|
2017 |
Open access
18
17
|
2016 |
Open access
37
36
|
2016 |
34
33
|
2016 |
31
29
|
2016 |
28
27
1
|
2016 |
34
35
|
2015 |
23
23
|
2015 |
30
28
4
|
2014 |
Open access
49
49
3
|
Patents
Prestidge & Joyce, ‘Novel Drug Delivery Composition Comprising Polymer-Lipid Hybrid Microparticles’ (PCT/AU2016/000080)
Research
Designing, engineering and applying innovative drug delivery solutions that overcome key biopharmaceutical challenges for the benefit of the wider community. Cutting edge biophysical and synthesis techniques are employed to develop novel strategies and technologies that are well-positioned for rapid clinical translation.
Research
Details | Registry | Status |
---|---|---|
Drug delivery composition comprising polymer-lipid hybrid microparticles Prestidge, Clive Allan; Joyce, Paul Matthew |
Australia | Filed |
External engagement & recognition
Organisation | Country |
---|---|
AstraZeneca (United Kingdom) | UNITED KINGDOM |
Chalmers University of Technology | SWEDEN |
CSIRO Australia (Commonwealth Scientific Industrial Research organisation) | AUSTRALIA |
Free University of Amsterdam | NETHERLANDS |
Glantreo Limited | IRELAND |
Hebrew University of Jerusalem | ISRAEL |
Humanitas University | ITALY |
Johnson & Johnson | UNITED STATES |
Macquarie University | AUSTRALIA |
Massey University | NEW ZEALAND |
Monash University | AUSTRALIA |
Oulun Yliopisto | FINLAND |
Radboud University Nijmegen | NETHERLANDS |
RMIT University | AUSTRALIA |
Russian Academy of Sciences | RUSSIAN FEDERATION |
SA Pathology | AUSTRALIA |
Saarland University | GERMANY |
South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
Stellenbosch University | SOUTH AFRICA |
Syrian-Lebanese Hospital (Brazil) | BRAZIL |
Tehran University of Medical Sciences | IRAN |
The Bowel Clinic London UK | UNITED KINGDOM |
Umeå University | SWEDEN |
University of Adelaide | AUSTRALIA |
University of Copenhagen | DENMARK |
University of Gothenburg | SWEDEN |
University of Groningen | NETHERLANDS |
University of Manitoba | CANADA |
University of New South Wales | AUSTRALIA |
University of Parma | ITALY |
University of Porto | PORTUGAL |
University of Santiago de Compostela | SPAIN |
University of South Australia | AUSTRALIA |
University of the Western Cape | SOUTH AFRICA |
University of Toronto | CANADA |
University of Trieste | ITALY |
Uppsala University | SWEDEN |
Vaxine Pty Ltd | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Chair of Frontiers in Bio-Nano Science 2021ARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2021 |
ECR RepresentativeAustralasian Society for Biomaterials and Tissue Engineering |
2021 |
MemberAmerican Association of Pharmaceutical Scientists |
2021 |
MemberAustralian Nanotechnology Network (ANN) |
2021 |
MemberEuropean Colloid & Interface Society |
2021 |
MemberAustralasian Colloid and Interface Society |
2021 |
MemberControlled Release Society |
2021 |
Outreach Committee MemberARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2021 |
STEM Professional in SchoolsCommonwealth Scientific and Industrial Research Organisation (CSIRO) |
2021 |
Topic EditorMembranes |
2021 |
Topic EditorAntibiotics |
2021 |
YourVoice Lung AdvocateLung Foundation Australia |
2021 |
Chair of Frontiers in Bio-Nano Science 2021ARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2020 |
ECR RepresentativeAustralasian Society for Biomaterials and Tissue Engineering |
2020 |
Keynote LectureRoyal Australian Chemical Institute (RACI) Chemistry Teachers Association |
2020 |
MemberAustralian Nanotechnology Network (ANN) |
2020 |
MemberAmerican Association of Pharmaceutical Scientists |
2020 |
MemberAustralasian Colloid and Interface Society |
2020 |
MemberEuropean Colloid & Interface Society |
2020 |
MemberControlled Release Society |
2020 |
Outreach Committee MemberARC Centre of Excellence in Convergent Bio-Nano Science and Technology |
2020 |
STEM Professional in SchoolsCommonwealth Scientific and Industrial Research Organisation (CSIRO) |
2020 |
Topic EditorMembranes |
2020 |
Topic EditorAntibiotics |
2020 |
YourVoice Lung AdvocateLung Foundation Australia |
2020 |
MemberAmerican Association of Pharmaceutical Scientists |
2019 |
MemberControlled Release Society |
2019 |
MemberAustralasian Pharmaceutical Science Association (APSA) |
2019 |
MemberEuropean Colloid & Interface Society |
2019 |
MemberAustralasian Colloid and Interface Society |
2019 |
MemberAustralian Nanotechnology Network (ANN) |
2019 |
Postdoctoral Research FellowshipAforsk Foundation |
2019 |
STEM Professional in SchoolsCommonwealth Scientific and Industrial Research Organisation (CSIRO) |
2019 |
Topic EditorAntibiotics |
2019 |
Keynote PresentationInternational Conference on Advanced Nano Materials |
2018 |
MemberAustralasian Pharmaceutical Science Association (APSA) |
2018 |
MemberControlled Release Society |
2018 |
MemberAustralasian Colloid and Interface Society |
2018 |
MemberEuropean Colloid & Interface Society |
2018 |
MemberAmerican Association of Pharmaceutical Scientists |
2018 |
Postdoctoral Research FellowshipAforsk Foundation |
2018 |
Best ECR Oral PresentationEuroFed Lipid Conference |
2017 |
Keynote LectureEuropean Colloid and Interface Science Symposium |
2017 |
MemberEuropean Colloid & Interface Society |
2017 |
MemberControlled Release Society |
2017 |
MemberAmerican Association of Pharmaceutical Scientists |
2017 |
MemberAustralasian Colloid and Interface Society |
2017 |
Postdoctoral Research FellowshipAforsk Foundation |
2017 |
MemberAustralasian Colloid and Interface Society |
2016 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
110496 - Lipid-based Nanocarrier Enabled Delivery for Improved T-cell Immunotherapy | Current |
110502 - Developing advanced oral delivery formulations for treating leukemia | Current |
111602 - Improving mental health therapies by targeting the gut microbiome | Current |
Amyloids of microbial biofilms mediate the host-microbe relationship and pro/pre-biotics enterprise | Current |
Conquering antimicrobial resistant Gram-negative bacteria to address unmet clinical needs | Current |
Design of Lipid Nanoparticles (LNPs) for mRNA-Based Cancer Vaccines | Current |
Developing advanced oral delivery systems for antiviral drugs | Current |
Development of a safe biomaterial-based therapy for obesity | Current |
Engineering Hybrid Materials with Functional Bioactivity in the GI Tract | Current |
Exploring the impact of formulation design on PUFA pharmacokinetics and biodistribution | Current |
Improving the efficacy of lung cancer therapies through targeted nanomedicine | Current |
Lipid-based formulations to overcome challenges in oral drugdelivery | Current |
Lymphatic Targeted Drug Delivery | Current |
Optimising treatment of haematological malignancies through the development of evidence-based dose individualisation strategies | Current |
Therapeutic targeting of vitamin D catabolism to prevent advanced breast cancer & metastases | Current |
Understanding the Biological Performance of Plant Derived Fats and Proteins - Towards Improved Meat Analogues | Current |
Beyond the gastrointestinal cell layer: replication of the complex oral absorption barrier through enhanced in vitro models for nanoparticulate oral protein delivery | Completed |
Lipid liquid crystalline nanoparticles: a delivery system for antimicrobial photodynamic therapy | Completed |
Overcoming biological barriers in treating intracellular infections using lipid-based nanoparticles | Completed |
Polymer-lipid hybrid microparticles enhance the intracellular uptake and activity of rifampicin against bacterially infected macrophages | Completed |